Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board:
Last Post: 7/25/2014 9:30:05 AM - Followers: 1092 - Board type: Free - Posts Today: 5
PostSubject
#180708  Sticky Note Sovaldi Warehousing and Otezla Trends Continue UBS ariadndndough 07/25/14 09:30:05 AM
#180694  Sticky Note FDA accepts for review NVS’ 351(k) Neupogen-FoB submission: DewDiligence 07/24/14 05:53:59 PM
#180692  Sticky Note Pfenex (PFNX) IPOs 9.58M* shares @$6.00 (way below DewDiligence 07/24/14 05:41:34 PM
#180678  Sticky Note Damn! It is not easy being a SRPT investor! Double_Bagel 07/24/14 07:34:24 AM
#180658  Sticky Note GILD posts $3.48B in 2Q14 Sovaldi sales (+53% DewDiligence 07/23/14 07:17:25 PM
#180080  Sticky Note What is your view on RGDO?From day one, DewDiligence 07/03/14 11:44:16 AM
#180708   Sovaldi Warehousing and Otezla Trends Continue UBS ariadndndough 07/25/14 09:30:05 AM
#180707   GILD—The 70% figure includes patients who took Sovaldi DewDiligence 07/25/14 09:19:48 AM
#180706   GILD vs ABBV dewophile 07/25/14 08:43:42 AM
#180705   GILD My friend, a top liver MD, says that zipjet 07/25/14 08:04:55 AM
#180704   Thanks for digging the figures. I assume the genisi 07/25/14 04:11:37 AM
#180703   Rocky, I think the time frame that doctors and justrpaul 07/24/14 11:54:13 PM
#180702   Before you answer those questions, how accurate are Rocky3 07/24/14 11:46:14 PM
#180701   >> They estimated that 70% of Sovaldi sales jq1234 07/24/14 11:35:42 PM
#180700   They estimated that 70% of Sovaldi sales were Rocky3 07/24/14 10:21:38 PM
#180699   Breo/Anoro: Just found info from GSK. Tier 2/3 jq1234 07/24/14 09:46:31 PM
#180698   yeah, theres almost a zero percent chance they BTH 07/24/14 09:02:24 PM
#180697   WF - CELG: Q2 2014--Favorable Setup Into H2 2014 ariadndndough 07/24/14 08:57:54 PM
#180696   >> GILD: initial TAF phase-3 data are reported jq1234 07/24/14 07:06:15 PM
#180695   ZMH -3% on lowered 2014 sales and EPS guidance: DewDiligence 07/24/14 06:16:46 PM
#180694   FDA accepts for review NVS’ 351(k) Neupogen-FoB submission: DewDiligence 07/24/14 05:53:59 PM
#180693   Deutsche Bank - Equity Research - North America CELG ariadndndough 07/24/14 05:45:42 PM
#180692   Pfenex (PFNX) IPOs 9.58M* shares @$6.00 (way below DewDiligence 07/24/14 05:41:34 PM
#180691   http://www.nasdaq.com/symbol/mnta/after-hours 472k block after hours at 10.99 Double_Bagel 07/24/14 04:49:31 PM
#180690   Agreed (eom). DewDiligence 07/24/14 04:23:49 PM
#180689   risk to GILD’s HIV franchise ciotera 07/24/14 04:03:19 PM
#180688   What do you think of GILD's valuation DewDiligence 07/24/14 03:33:55 PM
#180687   Dew, What do you think of GILD's valuation now? rajaram46 07/24/14 01:16:50 PM
#180686   Give credit to whoever designed the trial, and jq1234 07/24/14 01:08:04 PM
#180685   I don't know about Anoro since it was jq1234 07/24/14 12:47:56 PM
#180684   http://biz.yahoo.com/e/140724/onvo8-k.html On July 24, 2014, Organovo Holdings, Inc. north40000 07/24/14 12:28:13 PM
#180683   $SRPT Janney Capital Reiterates Sell On Sarepta Following maytepper 07/24/14 10:37:43 AM
#180682   Merrill. I do not get the underlying discussion, just ilpapa 07/24/14 08:05:53 AM
#180681   AEZS loading zone. Has multiple DRUG projects in GM_Tech 07/24/14 08:01:21 AM
#180680   <You have to give PBYI management enormous credit cooldrinkh2o 07/24/14 07:58:47 AM
#180679   Evogene Announces Amendment to Bayer Wheat Agreement to biotech jim 07/24/14 07:57:17 AM
#180678   Damn! It is not easy being a SRPT investor! Double_Bagel 07/24/14 07:34:24 AM
#180677   Tgtx ariadndndough 07/24/14 06:44:00 AM
#180676   GSK Advair U.S. sales tumbled 19 percentThis looks genisi 07/24/14 05:35:56 AM
#180675   GSK—mepolizumab should be a bright spot but will genisi 07/24/14 05:29:43 AM
#180674   HALO / Roche Herceptin update: From Roche's earnings call Double_Bagel 07/24/14 05:25:37 AM
#180673   pCR as endpoint for neoadjuvant setting is accelerated jq1234 07/24/14 02:54:05 AM
#180672   The best way to the market for 380 tony111 07/24/14 02:23:59 AM
#180671   Sorry, I didn't get to stick with the justrpaul 07/24/14 12:01:14 AM
#180670   ARIA> about 10 days ago I noticed a biocqr 07/23/14 11:31:24 PM
#180669   Gilead CC - Completely separate from Sovaldi, just mcbio 07/23/14 10:58:41 PM
#180667   ITMN: BIIB 2Q2014 earning call regarding Pirfenidone vs Nintedanib: jq1234 07/23/14 10:08:38 PM
#180666   BMY/Ono/(IPH.PA) - I-O Collaboration mcbio 07/23/14 09:20:41 PM
#180665   Just for the record, I am NOT ruling jq1234 07/23/14 09:00:02 PM
#180664   I am not sure ARRY management was stupid mcbio 07/23/14 08:39:19 PM
#180663   Well in vitro and in vivo animal data tony111 07/23/14 07:51:51 PM
#180662   >> Targeting EGF-1 might be an added benefit jq1234 07/23/14 07:36:31 PM
#180661   Gilead CC - justrpaul 07/23/14 07:30:14 PM
#180660   Sure pertuzumab seems to suggest inhibiting other family tony111 07/23/14 07:29:16 PM
#180659   INCY’s phase-3 trial of Jakafi in polycythemia vera DewDiligence 07/23/14 07:22:11 PM
#180658   GILD posts $3.48B in 2Q14 Sovaldi sales (+53% DewDiligence 07/23/14 07:17:25 PM
PostSubject